BioCentury
ARTICLE | Company News

Valeant sales and marketing update

April 27, 2017 9:07 PM UTC

Valeant priced psoriasis treatment Siliq brodalumab at a wholesale acquisition cost (WAC) of $3,500 per month, which it said is the lowest for a marketed injectable biologic psoriasis treatment. Competitor Humira adalimumab from AbbVie Inc. (NYSE:ABBV, Chicago, Ill.) has a monthly WAC of about $4,800. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) have monthly WACs of $4,308 and $4,422, respectively, according to the Red Book.

Of the four, Siliq is the only one that includes a boxed warning of suicidal ideation and behavior on its U.S. label...

BCIQ Company Profiles

Bausch Health Companies Inc.